CryoPort, Inc. (CYRX)

CryoPort's stock price has fluctuated in the past six months, influenced by financial results and analyst coverage. As of April 2, 2026, the share price was $8.77, a 59.74% increase from April 7, 2025. Key events impacting the stock include the Q4 and Full-Year 2025 Earnings Report, Q3 2025 Earnings Report, Q2 2025 Earnings Report, and new product introductions. CryoPort has a consensus rating of "Moderate Buy" from analysts, with an average price target of $12.94.

CryoPort's products and services are not significantly impacted by traditional seasonal demand fluctuations. Demand is primarily driven by the secular growth trends within the cell and gene therapy market. The increasing number of gene therapy programs in development and the growing acceptance of approved cell and gene therapies drive demand. The company has consistently reported strong year-over-year growth in its Life Sciences Services, indicating a steady and expanding demand.

CryoPort, Inc. is a global leader in temperature-controlled supply chain solutions for the life sciences industry, particularly in the cell and gene therapy market. The company operates in the Health Care sector, specifically Biotechnology: Pharmaceutical Preparations, and also Industrials and Integrated Freight & Logistics. CryoPort's core business ensures the safe transport and storage of temperature-sensitive biological materials. The company's major products and services are categorized into Life Sciences Services, which includes temperature-controlled logistics, biostorage, and cryopreservation, and Life Sciences Products, which manufactures and sells cryogenic freezers and related accessories. CryoPort supports a substantial number of global clinical trials and commercially approved therapies, holding approximately 70% of the cell and gene therapy clinical trial market.

CryoPort has a strong global presence with over 50 strategic locations across the Americas, EMEA, and APAC. Its corporate headquarters is in Brentwood, Tennessee. The company has established Global Supply Chain Centers (GSCCs) and logistics centers in key locations such as Morris Plains, New Jersey; Houston, Texas; Irvine, California; Amsterdam, Netherlands; Stevenage, UK; Sydney, Australia; Tokyo, Japan; and Louvres, France. These facilities provide integrated services including logistics, BioServices, biostorage, and cryopreservation.

CryoPort maintains a positive brand reputation within the life sciences industry. The company is recognized as a global leader in temperature-controlled supply chain solutions, especially for cell and gene therapies. Its integrated platform and strategic partnerships contribute to its strong market position and service reliability. News sentiment for CryoPort has been generally positive, with a news sentiment score of 0.34. The company's consistent double-digit revenue growth, expansion of services, and progress towards profitability have been highlighted.

CryoPort's ownership structure includes institutional, insider, and retail investors. Institutional shareholders hold a significant portion, between 47.93% and 89.63% of the company's stock. Major institutional owners include Cadian Capital Management LP, Morgan Stanley, and BlackRock, Inc. Jerrell Shelton, the CEO of CryoPort, is the largest individual shareholder, owning 1.06 million shares, representing 2.12% of the company.